Solaris Endovascular Inc.
About Solaris Endovascular Inc.
Solaris Endovascular, Inc. is a growth stage US-based medical device company developing advanced endovascular solutions for patients suffering from dialysis access challenges and peripheral artery disease. Founded in 2024 and headquartered in Dallas, Texas, the company’s Solaris DE platform received FDA Breakthrough Device Designation in 2026. It focuses on covered stents and drug-eluting technology to treat and extend the patency of dialysis access fistulae, grafts, and peripheral arteries. The company is revenue producing from the beginning with a decade-plus manufacturing expertise in stents, stent grafts, and endovascular drug delivery.
Investors
Key highlights
- Founded in 2024 in Dallas, TX, developing solutions for ESKD and PAD.
- Received FDA Breakthrough Device Designation for Solaris DE platform in 2026.
- Raised $4.97M via private placement / $5M convertible bridge round backed by UT Ventures.
- Revenue-producing from inception with proven stent and drug-eluting manufacturing expertise.
- Led by CEO Randy Hubbell and Chairman David Stack with extensive life sciences experience.
Ask StreetZero about Solaris Endovascular Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account